Renal

Localized

- T1b or greater (has not spread beyond the kidney)
  - IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy

Clear Cell

- No Prior Systemic Therapy
  - IRB#18121 Nivolumab Combined with Cabozantinib versus Sunitinib
- Matasectomy Candidate
  - IRB#16576 Atezolizumab vs placebo as adjuvant therapy following nephrectomy
  - IRB#17027 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology

Metastatic/locally advanced

- Prior Systemic Therapy
  - Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4
  - IRB#17027 A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology

Non-Clear Cell

- Papillary Renal Carcinoma
  - IRB#16085 S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

11/16/18

http://www.ohsu.edu/research/rda/so/knight.php